前列地尔联合贝那普利治疗早期糖尿病肾病临床观察  

Alprostadil combined with benagepril therapy of early diabetic nephropathy

作　　者：区冰玲[1] 林宏初[1] 郑东文[1] 

机构地区：[1]东莞市人民医院,广东523018

出　　处：《国际泌尿系统杂志》2010年第1期30-31,共2页International Journal of Urology and Nephrology

摘　　要：目的观察前列地尔联合贝那普利治疗早期糖尿病肾病（DN）的疗效。方法将DN患者随机分为2组，在常规治疗的同时，A组服用贝那普利，B组前列地尔联合贝那普利治疗，时间均为2周，比较2组治疗前后尿自蛋白排泄率（UAER）的变化。结果两组治疗前后UAER均有显著下降（A组P〈0．05，B组P〈0．01），B组与A组比较差异有统计学意义（P〈0．05）。结论前列地尔联合贝那普利列地尔注射液是治疗糖尿病肾病的有效方法。Objectives To observe the effect of alprostadil combined with benazepril treating of early dia- betic nephropathy （DN）. Methods DN were randomly divided into two groups, while in the conventional thera- py,A group were treated with benazepril, B group of alprostadil combined with benazepril treatment, the time is 2 weeks, compared two groups before and after treatment of urine from the prolein excretion rate （ UAER ） cbanges. Results UAER groups before and after treatment were significantly decreased （ A group ofp 〈 0.05, B group p 〈0. 01 ）, B group and A group difference was statistically significant （ p 〈 0.05 ）. Conclusions Alprostadil combined with benazepril out Diltiazem injection is an effective method of treatment of diabetic nephropathy.

关 键 词：糖尿病肾病 前列地尔 血管紧张素转换酶抑制药 

分 类 号：R587.2[医药卫生—内分泌] R692.9[医药卫生—内科学]